Federal program funds addiction treatment hubs in high-overdose communities

What it does

This bill creates a five-year federal demonstration program under Medicaid to fund 'Health Engagement Hubs'—drop-in centers in high-overdose communities that provide opioid and substance use disorder treatment, harm reduction supplies, mental health services, and wraparound social services (housing help, legal aid, employment counseling). States apply to participate; the federal government covers 90% of costs through a prospective payment system. The bill appropriates $60 million for planning grants, administration, and evaluation.

Why we flagged it

The bill's operative mechanism is a federal-state partnership to establish and fund community-based addiction treatment and harm reduction centers. It is a public health infrastructure investment, not a regulatory change, tax provision, or private subsidy.

What the text implies

• The bill requires at least 50% of hubs in high-overdose counties or mental health shortage areas, but does not mandate rural coverage—rural areas may be underserved if they fall outside these criteria, potentially widening geographic disparities in access.
• The prospective payment system is state-designed and state-administered; variation across states may create inconsistent service quality, reimbursement rates, and eligibility standards, making outcomes difficult to compare and potentially disadvantaging residents of lower-resourced states.
• Hubs must provide access to FDA-approved opioid use disorder medications (buprenorphine, methadone, naltrexone) within 4 hours, but the bill does not specify whether states must fund these medications or whether they fall under existing Medicaid drug rebate agreements—cost allocation is ambiguous.
• The bill requires community advisory boards with lived experience, but does not specify voting power, decision-making authority, or enforcement mechanisms if organizations ignore their recommendations, limiting accountability.
• Evaluation is contracted to a third party and results are reported to Congress and the public, but the bill does not specify what happens if a state's program is found ineffective—there is no explicit authority to terminate or redirect funding mid-program.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands access to evidence-based addiction treatment and harm reduction services in underserved, high-overdose communities, with explicit requirements for peer staffing, trauma-informed care, and sliding-scale fees for uninsured individuals. It does not restrict citizens' rights or remedies; it creates new public health infrastructure. The 90% federal match reduces state fiscal burden and incentivizes participation.

Who stands to gain

• Federally qualified health centers and community health centers (as partner organizations)
• Substance use disorder treatment providers and clinics (as partner organizations)
• Pharmaceutical manufacturers of opioid use disorder medications (buprenorphine, methadone, naltrexon
• Evaluation contractors

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS), State Medicaid agencies, Federally qualified health centers (FQHCs), Indian tribes and tribal organizations, Urban Indian organizations, Substance use disorder treatment providers, Peer support specialists and community health workers, Government Accountability Office (GAO), Senate Committee on Finance, House Committee on Energy and Commerce

Where it stands

1 cosponsor: 1 Republicans.

• Feb 20, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Feb 20, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 6 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,790,433 in lobbying spend. A filing names 30 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Maria Cantwell, the sponsor, reported $-9,000 in PAC receipts in the 2026 cycle.

• Greater New York Hospital Association — $1,130,000 on 2 filings
• College of American Pathologists — $640,433 on 3 filings
• National Alliance on Mental Illness — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.